THE USE OF ELECTRONIC PATIENT-REPORTED OUTCOMES SYSTEM «HEALTH - ELECTRONIC SELF-ASSESSMENT» (HESA) IN ROUTINE CLINICAL PRACTICE FOR HEALTH STATUS MONITORING IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES UNDERGOING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)

Rationale: during auto-HSCT, it is of great importance to monitor the patient’s condition after discharge for control of side effects, correction of accompanying therapy and assessing the patient’s recovery.
Objective: to study the dynamics of quality of life (QoL) and symptoms in patients with hematological malignancies after auto-HSCT using the electronic HESA system (Health – Electronic Self-Assessment).
Methods: The data were analyzed in patients with hematological malignancies who underwent auto-HSCT from March 2023 to November 2024. Patients filled out questionnaires based on HESA before auto-HSCT and at discharge, as well as remotely at different times after discharge. HESA is a secure web platform based on standardized HM-PRO and HADS questionnaires. Data obtained using HESA were used to analyze the dynamics of QoL by HM-PRO and dynamics of anxiety/depression by HADS and to identify significant changes in QoL and psychological health at different times after discharge.
Results: the data were obtained on 119 patients (male/female 55/64) aged from 19 years to 72 years (mean age 43 years); 48% patients had Hodgkin lymphoma (HL), 21% – non-Hodgkin lymphoma (NL) and 31% – multiple myeloma (MM). Prior to auto-HSCT, 56% of patients had significantly impairment of emotional functioning, 42% – physical functioning, 20% – social functioning, and 40% had significant problems due to impaired eating and drinking habits. In 40% of patients, symptoms had a significant impact on their condition. Most often, patients experienced severe fatigue (69%), insufficient energy (65%) and hair loss (43%). 14% and 10% of patients had borderline/elevated levels of anxiety/depression. After discharge, 38% of patients completed HESA remotely (maximum duration of monitoring – 22 months, median – 11 months). During monitoring, a part of patients recorded a deterioration in certain indicators: 38% – in terms of QoL impairment, 18% – in terms of symptom effect; 18% and 27% have an increase in anxiety and depression, respectively. At the end of the follow-up 29% patients had significant negative dynamics in QoL, 16% – significant increase in the symptoms effect. In 16% and 24%, respectively, the increasing of anxiety and depression was revealed. The treating physicians used information, obtained with HESA for interaction with patients to optimize the accompanying therapy.
Conclusion: the use of HESA in patients with hematological malignancies undergoing auto-HSCT should be used for timely interaction with the patient and can contribute to the implementation of patient-oriented care.

1. Balashov DN, Shelikhova LN, Maschan MA. Transplantatsiya gemopoeticheskikh stvolovykh kletok: pokazaniya, vidy transplantatsiy, vybor donora. Voprosy gematologii/onkologii i immunopatologii v pediatrii. 2022; 21(2): 131-135. (In Russ.) doi: 10.24287/j.626.

2. Transplantatsiya autologichnykh gemopoeticheskikh stvolovykh kletok pri gemoblastozakh. Metodicheskoe rukovodstvo. Moscow: Natsional’noe gematologicheskoe obshchestvo; 2020. (In Russ.)

3. Goswami P, Oliva EN, Ionova T, et al. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study. Ther Adv Hematol. 2020; 11: 2040620720955002. doi: 10.1177/2040620720955002.

4. Efficace F, Gaidano G, Lo-Coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood. 2017; 130(7): 859-866. doi: 10.1182/blood-2017-03-737403.

5. Hayes CA, Van Citters AD, Zhao W, et al. Patient-Reported Outcomes in Hematopoietic Stem Cell Transplant Recipients: Design, Implementation, and Pilot Results. J Clin Pathways. 2024; 10(2): 17-22. doi:10.25270/jcp.2024.03.02.

6. D’Souza A, Brazauskas R, Stadtmauer EA, et al. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023; 98(1): 140-147. doi: 10.1002/ajh.26596.

7. Georges GE, Bar M, Onstad L, et al. Survivorship after Autologous Hematopoietic Cell Transplantation for Lymphoma and Multiple Myeloma: Late Effects and Quality of Life. Biol Blood Marrow Transplant. 2020; 26(2): 407-412. doi: 10.1016/j.bbmt.2019.10.002.

8. Ortolá-Alonso P, Santacatalina-Roig E, Chover-Sierra E, et al. Hematopoietic Stem Cell Transplantation Impact on Patients’ Perceived Quality of Life: A Longitudinal Study. Nursing Reports. 2024; 14(1): 197-211. doi: 10.3390/nursrep14010016.

9. Meirte J, Hellemans N, Anthonissen M, et al. Benefits and Disadvantages of Electronic Patient-reported Outcome Measures: Systematic Review. JMIR Perioper Med. 2020; 3(1): e15588. doi: 10.2196/15588.

10. Basch E, Mody GN, Dueck AC. Electronic Patient-Reported Outcomes as Digital Therapeutics to Improve Cancer Outcomes. JCO Oncol Pract. 2020 Sep; 16(9): 541-542. doi: 10.1200/OP.20.00264.

11. Nikitina T, Efremov S, Melnichenko V, et al. Using Digital Technologies for Monitoring Patient’s Well-being and Quality of Life. Hematology. Transfusiology. Eastern Europe. 2023; 9(3): 342-356. (In Russ.) doi: 10.34883/PI.2023.9.3.001.

12. Nikitina TP, Melnichenko VYa, Fedorenko DA, et al. Development and Testing of Electronic Patient-Reported Outcome System “Health – Electronic Self-Assessment” (HESA) for Monitoring the Health Status of Patients with Hematologic Malignancies Based on Their Quality-of-Life Data. Clinical oncohematology. 2024; 17(4): 390-403. (In Russ.) doi: 10.21320/2500-2139-2024-17-4-390-403.

13. Goswami P, Oliva EN, Ionova T, Salek S. Translating the Science of Patient Reported Outcomes into Practice: Meaningfulness of HM-PRO Scores in Patients with Hematological Malignancies. Blood. 2018; 132(1): 4860-4860. doi: 10.1182/blood-2018-99-117180.

14. Ionova TI, Bannikova AEu, Bykova AV, et al. Development and psychometric evaluation of the specific questionnaire for quality of life assessment in patients with hematological malignancies in clinical practice – HM-PRO. Bulletin of the Multinational Center for Quality of Life Research. 2020; 35-36: 86-104. (In Russ.)

15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6): 361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.

16. Nikitina TP, Melnichenko VYa, Fedorenko DA, Sarzhevskiy VO, et al. Use of electronic patient-reported outcome system in routine clinical practice in patients with lymphoproliferative neoplasms undergoing autologous hematopoietic stem cell transplantation: a feasibility study. Cell Ther Transplant 2024; 13(3): 60-67.

17. Nakano J, Fukushima T, Tanaka K, et al. Anxiety, depression, physical symptoms, and activity in patients with hematological malignancy undergoing chemotherapy: A cross-sectional study. Int Med Care. 2019; 3: 2-6. doi: 10.15761/IMC.1000130.

18. Johnson PC, Bhatt S, Reynolds MJ, et al. Association Between Baseline Patient-Reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021; 27(6): 496.e1-496.e5. doi: 10.1016/j.jtct.2021.02.029.

19. El-Jawahri AR, Vandusen HB, Traeger LN, et al. Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation. Cancer. 2016; 122: 806-812. doi: 10.1002/cncr.29818.

20. Newcomb R, Amonoo HL, Nelson AM, et al. Coping in patients with hematologic malignancies undergoing hematopoietic cell transplantation. Blood. 2024; 8(6): 1369-1378. doi: 10.1182/bloodadvances.2023011081.